Buy or sell Roivant Sciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Roivant Sciences Stock

Biopharmaceutical company

Founded

2014

Notable Investors

Dexcel Pharma

Headquarters

Basel , CH

Total Funding

$1.9B

About Roivant Sciences Stock

Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.

Investors

Funding History

May 2014$93.0M
July 2016$500M
August 2017$1.1B
November 2018$200M

Management

Co-Founder & Chief Executive Officer

Vivek Ramaswamy

Chief Information Officer

Daniel Rothman

Chief Financial Officer

Matthew Gline

Chief Accounting Officer

Rakhi Kumar

Press

Other Companies

Logo
10X Genomics

Innovative Genomics Platform

Logo
CRISPR Therapeutics

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Logo
PanTheryx

Intestinal health research, development, and commercialization products

Logo
Practo

Online appointment management for doctors and patients in India

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Roivant Sciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo

Logo